F3 has licensed the following Patents from the University of Chicago:

  • One granted U.S. patent
  • Pending IP across multiple indications
  • One granted European patent (validated in Germany, France, UK, Belgium, Turkey, Greece, Hungary, Poland, Spain, the Netherlands, Italy)

Guided by the extensive research of our Scientific Advisory Team, F3 has secured a meaningful IP portfolio to bring the AmiGuard platform to market globally across a broad array of indications and formulations.